Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug

Daniele Sanna, Valeria Ugone, Giovanni Micera, P. Buglyó, Linda Bíró, Eugenio Garribba

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The first report on the anti-cancer activity of the compound Metvan, [VIVO(Me2phen)2(SO4)], where Me2phen is 4,7-dimethyl-1,10-phenanthroline, dates back to 2001. Although it was immediately identified as one of the most promising multitargeted anti-cancer V compounds, no development on the medical experimentation was carried out. One of the possible reasons is the lack of information on its speciation in aqueous solution and its thermodynamic stability, factors which influence the transport in the blood and the final form which reaches the target organs. To fill this gap, in this work the speciation of Metvan in aqueous solution and human blood was studied by instrumental (EPR, electronic absorption spectroscopy, ESI-MS and ESI-MS/MS), analytical (pH-potentiometry) and computational (DFT) methods. The results suggested that Metvan transforms at physiological pH into the hydrolytic species cis-[VO(Me2phen)2(OH)]+ and that both citrate and proteins (transferrin and albumin in the blood serum, and hemoglobin in the erythrocytes) form mixed complexes, denoted [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein with the probable binding of His-N donors. The measurements with erythrocytes suggest that Metvan is able to cross their membrane forming mixed species VO-Me2phen-Hb. The redox stability in cell culture medium was also examined, showing that ca. 60% is oxidized to VV after 5 h. Overall, the speciation of Metvan in the blood mainly depends on the V concentration: when it is larger than 50 μM, [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein are the major species, while for concentrations lower than 10 μM, (VO)(hTf) is formed and Me2phen is lost. Therefore, it is plausible that the pharmacological activity of Metvan could be due to the synergic action of free Me2phen, and VIVO and VVO/VVO2 species.

Original languageEnglish
Pages (from-to)8950-8967
Number of pages18
JournalDalton Transactions
Volume46
Issue number28
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Vanadium
Tumors
Blood
Pharmaceutical Preparations
Proteins
Transferrin
Absorption spectroscopy
Cell culture
Discrete Fourier transforms
Citric Acid
Paramagnetic resonance
Culture Media
bis(4,7-dimethyl-1,10-phenanthroline)sulfatooxovanadium(IV)
Albumins
Hemoglobins
Thermodynamic stability
Membranes

ASJC Scopus subject areas

  • Inorganic Chemistry

Cite this

Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug. / Sanna, Daniele; Ugone, Valeria; Micera, Giovanni; Buglyó, P.; Bíró, Linda; Garribba, Eugenio.

In: Dalton Transactions, Vol. 46, No. 28, 01.01.2017, p. 8950-8967.

Research output: Contribution to journalArticle

Sanna, D, Ugone, V, Micera, G, Buglyó, P, Bíró, L & Garribba, E 2017, 'Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug', Dalton Transactions, vol. 46, no. 28, pp. 8950-8967. https://doi.org/10.1039/c7dt00943g
Sanna, Daniele ; Ugone, Valeria ; Micera, Giovanni ; Buglyó, P. ; Bíró, Linda ; Garribba, Eugenio. / Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug. In: Dalton Transactions. 2017 ; Vol. 46, No. 28. pp. 8950-8967.
@article{d9b56d79f966470191ee3beef0cd9cda,
title = "Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug",
abstract = "The first report on the anti-cancer activity of the compound Metvan, [VIVO(Me2phen)2(SO4)], where Me2phen is 4,7-dimethyl-1,10-phenanthroline, dates back to 2001. Although it was immediately identified as one of the most promising multitargeted anti-cancer V compounds, no development on the medical experimentation was carried out. One of the possible reasons is the lack of information on its speciation in aqueous solution and its thermodynamic stability, factors which influence the transport in the blood and the final form which reaches the target organs. To fill this gap, in this work the speciation of Metvan in aqueous solution and human blood was studied by instrumental (EPR, electronic absorption spectroscopy, ESI-MS and ESI-MS/MS), analytical (pH-potentiometry) and computational (DFT) methods. The results suggested that Metvan transforms at physiological pH into the hydrolytic species cis-[VO(Me2phen)2(OH)]+ and that both citrate and proteins (transferrin and albumin in the blood serum, and hemoglobin in the erythrocytes) form mixed complexes, denoted [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein with the probable binding of His-N donors. The measurements with erythrocytes suggest that Metvan is able to cross their membrane forming mixed species VO-Me2phen-Hb. The redox stability in cell culture medium was also examined, showing that ca. 60{\%} is oxidized to VV after 5 h. Overall, the speciation of Metvan in the blood mainly depends on the V concentration: when it is larger than 50 μM, [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein are the major species, while for concentrations lower than 10 μM, (VO)(hTf) is formed and Me2phen is lost. Therefore, it is plausible that the pharmacological activity of Metvan could be due to the synergic action of free Me2phen, and VIVO and VVO/VVO2 species.",
author = "Daniele Sanna and Valeria Ugone and Giovanni Micera and P. Bugly{\'o} and Linda B{\'i}r{\'o} and Eugenio Garribba",
year = "2017",
month = "1",
day = "1",
doi = "10.1039/c7dt00943g",
language = "English",
volume = "46",
pages = "8950--8967",
journal = "Dalton Transactions",
issn = "1477-9226",
publisher = "Royal Society of Chemistry",
number = "28",

}

TY - JOUR

T1 - Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug

AU - Sanna, Daniele

AU - Ugone, Valeria

AU - Micera, Giovanni

AU - Buglyó, P.

AU - Bíró, Linda

AU - Garribba, Eugenio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The first report on the anti-cancer activity of the compound Metvan, [VIVO(Me2phen)2(SO4)], where Me2phen is 4,7-dimethyl-1,10-phenanthroline, dates back to 2001. Although it was immediately identified as one of the most promising multitargeted anti-cancer V compounds, no development on the medical experimentation was carried out. One of the possible reasons is the lack of information on its speciation in aqueous solution and its thermodynamic stability, factors which influence the transport in the blood and the final form which reaches the target organs. To fill this gap, in this work the speciation of Metvan in aqueous solution and human blood was studied by instrumental (EPR, electronic absorption spectroscopy, ESI-MS and ESI-MS/MS), analytical (pH-potentiometry) and computational (DFT) methods. The results suggested that Metvan transforms at physiological pH into the hydrolytic species cis-[VO(Me2phen)2(OH)]+ and that both citrate and proteins (transferrin and albumin in the blood serum, and hemoglobin in the erythrocytes) form mixed complexes, denoted [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein with the probable binding of His-N donors. The measurements with erythrocytes suggest that Metvan is able to cross their membrane forming mixed species VO-Me2phen-Hb. The redox stability in cell culture medium was also examined, showing that ca. 60% is oxidized to VV after 5 h. Overall, the speciation of Metvan in the blood mainly depends on the V concentration: when it is larger than 50 μM, [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein are the major species, while for concentrations lower than 10 μM, (VO)(hTf) is formed and Me2phen is lost. Therefore, it is plausible that the pharmacological activity of Metvan could be due to the synergic action of free Me2phen, and VIVO and VVO/VVO2 species.

AB - The first report on the anti-cancer activity of the compound Metvan, [VIVO(Me2phen)2(SO4)], where Me2phen is 4,7-dimethyl-1,10-phenanthroline, dates back to 2001. Although it was immediately identified as one of the most promising multitargeted anti-cancer V compounds, no development on the medical experimentation was carried out. One of the possible reasons is the lack of information on its speciation in aqueous solution and its thermodynamic stability, factors which influence the transport in the blood and the final form which reaches the target organs. To fill this gap, in this work the speciation of Metvan in aqueous solution and human blood was studied by instrumental (EPR, electronic absorption spectroscopy, ESI-MS and ESI-MS/MS), analytical (pH-potentiometry) and computational (DFT) methods. The results suggested that Metvan transforms at physiological pH into the hydrolytic species cis-[VO(Me2phen)2(OH)]+ and that both citrate and proteins (transferrin and albumin in the blood serum, and hemoglobin in the erythrocytes) form mixed complexes, denoted [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein with the probable binding of His-N donors. The measurements with erythrocytes suggest that Metvan is able to cross their membrane forming mixed species VO-Me2phen-Hb. The redox stability in cell culture medium was also examined, showing that ca. 60% is oxidized to VV after 5 h. Overall, the speciation of Metvan in the blood mainly depends on the V concentration: when it is larger than 50 μM, [VO(Me2phen)(citrH-1)]2- and VO-Me2phen-Protein are the major species, while for concentrations lower than 10 μM, (VO)(hTf) is formed and Me2phen is lost. Therefore, it is plausible that the pharmacological activity of Metvan could be due to the synergic action of free Me2phen, and VIVO and VVO/VVO2 species.

UR - http://www.scopus.com/inward/record.url?scp=85024899403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024899403&partnerID=8YFLogxK

U2 - 10.1039/c7dt00943g

DO - 10.1039/c7dt00943g

M3 - Article

C2 - 28640312

AN - SCOPUS:85024899403

VL - 46

SP - 8950

EP - 8967

JO - Dalton Transactions

JF - Dalton Transactions

SN - 1477-9226

IS - 28

ER -